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Abstract. Translational research is generally described as the application of basic science discoveries to
the treatment or prevention of disease or injury. Its value is usually determined based on the likelihood
that exploratory or developmental research can yield effective therapies. While the pharmaceutical
industry has evolved into a highly specialized sector engaged in translational research, the academic
medical research community has similarly embraced this paradigm largely through the motivation of the
National Institute of Health (NIH) via its Roadmap initiative. The Clinical and Translational Science
Award (CTSA) has created opportunities for institutions which can provide the multidisciplinary
environment required to engage such research. A key component of the CTSA and an element of both
the NIH Roadmap and the FDA Critical Path is the bridging of bench and bedside science via
quantitative pharmacologic relationships. The infrastructure of the University of Pennsylvania/Children’s
Hospital of Philadelphia CTSA is highlighted relative to both research and educational objectives reliant
upon quantitative pharmacology. A case study, NIH-sponsored research program exploring NK1r
antagonism for the treatment NeuroAIDS is used to illustrate the application of quantitative
pharmacology in a translational research paradigm.
KEY WORDS: Model-baseddrugdevelopment; NIH Roadmap; Quantitative pharmacology; Translational
research.
INTRODUCTION
Academic research is an important component in the
discovery and development of new molecular entities. Like
their industrial and regulatory colleagues, academic scientists
are engaged in responding to a changing R&D landscape
which demands both efﬁciency and innovation. The concept
of translational research has evolved over the past decade and
haslikewisebeendeﬁnedinmanyways.Areasonabledeﬁnition
for translational research would be the application of basic
scientiﬁc discoveries into clinically germane ﬁndings and,
simultaneously, the generation of scientiﬁc questions based on
clinical observations (1). A more lucid understanding can be
found in the utilization of translational research methodologies
in speciﬁc therapeutic areas such as oncology (2,3), nephrol-
ogy (4), pain management (5), and cognitive decline with aging
(6). The historical and parallel context to be considered when
discussing the genesis of translational research is that while big
and small Pharmaceutical Manufacturers Association
(PhRMA) companies were contending with diminishing pipe-
lines despite improvements in high throughput screening and
other discovery-based innovations, academic medical centers
were at a loss for how to connect the basic sciences in the
post-genomic era to clinical researchers who had heard of
the “bench” but had seldom visited. At the same time,
their governing regulatory counterparts crafted the critical
path (7) and roadmap (8) initiatives from the Food and Drug
Administration (FDA) and National Institute of Health
(NIH) respectively to address these concerns and provide
suggestions for resolution. At the core of these proposals is a
clear request for the creation of interdisciplinary teams that will
deﬁne quantitative relationships bridging discovery and devel-
opmental science and challenging hypotheses regarding basic
and clinical pharmacology, facilitating novel experimental
designs and aiding in drug development decision making in
general—“quantitative pharmacology”for lack of a better name.
NIH ROADMAP AND THE CLINICAL
AND TRANSLATION SCIENCE AWARD (CTSA)
Academic research is funded by a variety of mechanisms
including the public and private sectors with the major
investment coming from the NIH which will use much of its
projected $28.6 billion 2007 budget to fund biomedical
research in the United States (9). The structure of the NIH
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has historically created a compartmentalized focus on disease
research; counter to new paradigms which encourage multidis-
ciplinary teams and the basic-to-applied research continuum in
general. The NIH Roadmap initiative (http://nihroadmap.nih.
gov) seeks to resolve this infrastructure barrier and aims to
accelerate translational research (10). Its main goal is “to
identify major opportunities and gaps in biomedical research
that no single institute at NIH could tackle alone.” The
roadmap covers three main themes:
& “New Pathways to Discovery”: to stimulate the
development of novel approaches to unravel the
complexity of biologic systems and their regulation
& “Research Teams of the Future”:t or e d u c et h e
cultural and administrative barriers that often impede
research and invoke an era in which scientists can
cooperate in new and different ways
& “Re-engineering the Clinical Research Enterprise”:
to fund facilities, resources, or both to bolster clinical
and translational research.
The Clinical and Translational Science Awards (CTSAs)
were created as an outgrowth of the roadmap initiative.
Interested applicants will propose transformative efforts ap-
propriate to their own institutions (http://grants.nih.gov/grants/
guide/notice-ﬁles/NOT-RM-05-013.html). The nature of these
proposals should address educational programs, describe
career pathway proposals for scientists investing in translation-
al research, and provide a research environment that is ﬂexible
and both conducive to and responsive to the demands of
modern translational and clinical research. The intention of the
CTSA primary author, Dr. Zerhouni is that, “the CTSAs will
advance the assembly of institutional academic homes provid-
ing integrated intellectual and physical resources for the
conduct of original clinical and translational science (11,12).”
Speciﬁcally, the NIH has asked applicants to consolidate
General Clinical Research Centers (GCRCs), T32 and K12
programs, and other resources as appropriate as they propose
their individual integrated programs. Resources may be
augmented by NIH Roadmap funding redirected from other
initiatives andtargeted to theCTSAprogram, with theNational
Center for Research Resources. The NIH consortium recently
added12moreacademichealthcenterstothe12announcedlast
October (2006)—the funding through the CTSA program
totaled $108 million the ﬁrst year. A third funding opportunity
announcement for CTSAs has been issued, calling for the next
roundofapplicationsto be submitted byNovember7, 2007with
the awards expected in June 2008. This funding announcement
andotherinformationabout the CTSAProgram areavailableat
www.ncrr.nih.gov/ctsa.asp. When fully implemented in 2012, 60
institutions will be linked together to invigorate the discipline
of clinical and translational science (http://www.ctsaweb.org/).
The awards are for 5 years and the program itself will
eventually replace the GCRCs (13).
THE UNIVERSITY OF PENNSYLVANIA/CHILDREN’S
HOSPITAL OF PHILADELPHIA CTSA
One of the initial 12 CTSA recipients was the University
of Pennsylvania (Penn) and its partner institutions, the
Children’s Hospital of Philadelphia (CHOP), the Wistar
Institute and the University of the Sciences in Philadelphia
(Pharmacy). Their application included participation from the
Schools of Medicine, Nursing, Dentistry, Education, Arts and
Sciences, Veterinary, Engineering and Applied Sciences, the
Annenberg School of Communications, and the Wharton
Business School within Penn combined with colleagues from
external partnerships into novel, interdisciplinary structures
and programs. Penn and CHOP, together with their partner
institutions include a large critical mass of senior faculty
accomplished in the translation of a diverse array of therapeu-
tic modalities—small molecules, proteins, genes, vaccines—
into the clinical domain. Together they have a remarkable
training record—more NIH supported training grants than any
other institution, the largest medical science training program
in the country and multiple junior faculty holding K awards.
They also have two well established NIH funded GCRCs with
potential to bridge the pediatric/adult interface. Finally, the
group represents a single geographic campus facilitating the
engagement of chemists, engineers, statisticians, nurses, veter-
inarians, dentists, pharmacists, policy makers and shapers and
experts in commercialization with biomedical scientists, epi-
demiologists and physicians.
The Penn/CHOP transformational plan involves a com-
mitment by the institutions involved to (a) collaborate and
support the recruitments and programs in the ﬁeld of clinical
and translational research; (b) devote substantial space (wet
and dry laboratories) to clinical and translational research; and
(c) foster the trans-institutional expansion of the “academic
home” of this enterprise—the Institute for Translational
Medicine and Therapeutics (ITMAT)—to permit develop-
ment of new centers, cores and interdisciplinary programs of
research and education (14). An important goal for the Penn/
CHOP plan is the development of focused strategic alliances
with the FDA and the pharmaceutical and computing
industries. Besides these alliances, the engagement of Bio-
Advance (http://www.bioadvance.com), a state funded entity
charged with fostering the development of the life sciences in
southeastern Pennsylvania has also been secured. BioAdv-
ance will assist in providing resource for the access of trainees
based with primary appointments in regional institutions to
these educational instruments and will also support the
development of and regionalization of access to bioinfor-
matics platforms developed through the CTSA. Figure 1
shows the various centers which comprise ITMAT with the
associated cores which will service the Translational Research
Center. The support of quantitative pharmacology practice will
be provided by the KMAS (Kinetic Modeling and Simulation)
Core (http://www.med.upenn.edu/kmas/) which will (a) aid in
the development of drug assays; (b) promote and assist in the
performance of tracer kinetic studies; (c) develop novel
approaches to kinetic data analysis; (d) provide PK, PK/PD,
and tracer kinetic modeling; and (e) develop educational
modules in pharmacokinetics and tracer kinetics to populate
the educational initiatives pursued within the CTSA.
A central mission of ITMAT has been education. The
deﬁciency of human capital in translational research, partic-
ularly with respect to the development and evaluation of new
medicines is well appreciated and pervasive in industry,
academia and the regulatory community (15). Figure 2
contains a schematic of the proposed educational program
10 BarrettFig. 2. The Penn/CHOP educational program proposed for the CTSA targets the full spectrum of potential and existing
trainees, from undergraduates to graduate students, fellows, and faculty. As individuals require different levels and types of
training at each stage of their academic development, multiple options are provided for exposure to translational research
ranging from preview/awareness courses to certiﬁcation, masters and doctoral degree programs
Fig. 1. Institute for Translational Medicine and Therapeutics (ITMAT) Centers proposed
within the Penn/CHOP CTSA grant and the new cores supporting the Translational Research
Center. The KMAS (Kinetic Modeling and Simulation) core will provide technologic expertise
for integration of quantitative pharmacology into the translational research paradigm
11 Quantitative Pharmacology in an Academic Research Environmentsupported by the Penn/CHOP CTSA. The ITMAT had
proposed the name “Translational Medicine and Therapeu-
tics” to embrace the projection of basic disciplines into the
clinical domain with the objective of developing novel
therapeutics. Such individuals would be trained in the
development and projection of mechanism based biomarkers
from cellular and model systems to guide rational dose
selection. Furthermore, they would be trained to apply the
emerging use and bioinformatic analysis of output from
technologies, such as proteomics, metabolomics and
genomics, to select between diverse molecules directed at a
singular target. While the KMAS core will provide functional
support of quantitative pharmacology activities, a Pharmaco-
metric Training Unit will provide educational and training
resources in addition to previously created programs in
translational medicine. Initially, a module on tracer kinetics,
pharmacokinetics, and compartmental and pharmacometric
modeling will be offered as a core requirement in a Transla-
tional Therapeutics track and electively as a stand alone course
or a component in other degree courses administered via
ITMAT in support of the CTSA. PhRMA and FDA staff will
participate, both as faculty participants and as sites for rotation
site for CTSA students. In addition, scientists from the Metrum
Institute (http://metruminstitute.org/about.html), a nonproﬁt
organization dedicated to the advancement of quantitative
modeling and simulation in biomedical research, with particu-
Fig. 3. An example of quantitative pharmacologic principles applied to translational research: Relationships with aprepitant from in vitro data,
in vivo data in animals, and in vivo data in CINV patients used to predict HIV-infected patient response and NeuroAIDS disease progression
12 Barrettlar emphasis on problems in clinical pharmacology and
therapeutics, will also serve as faculty. BioAdvance will
facilitate regionalization of access to this program.
CASE STUDY: NK1R ANTAGONISM IN NEUROAIDS
An example of the integration of the quantitative
pharmacology approach applied to an academic translational
research initiative can be illustrated with recent efforts to
explore NK1 receptor antagonism to treat NeuroAIDS.
NeuroAIDS as a target indication is yet to be recognized as
a separate therapeutic area by PhRMA companies though
neurological complications associated with HIV-1/AIDS are
being recognized with a frequency that parallels the increased
number of AIDS cases. The early inﬁltration by HIV-1 into
the nervous system can cause primary and/or secondary
neurological complications. Likewise, these complications
have been shown to ultimately inﬂuence patient compliance
with their antiretroviral therapy. The National Institutes of
Allergy and Infectious Disease and the National Institutes of
Mental Health of the NIH (PAR-03–138) have funded the
establishment of a multidisciplinary research and develop-
ment program targeted toward the discovery, development
and evaluation of innovative therapies for HIV infection
(http://grants.nih.gov/grants/guide/pa-ﬁles/PAR-03-138.html).
The overall goal of the program is to support and accelerate
scientiﬁc and technical progress in non-traditional and
traditional drug-based therapies that exploit novel viral and
cellular targets of importance in HIV infection. A benchmark
for a successful program is the development of a new
treatment concept that can be introduced to clinical practice.
The ability of neurokinin-1 receptor (NK-1R) antagonists to
target the substance P receptor demonstrating antiviral and
immunomodulatory effects (16–18) represents a new thera-
peutic target with the potential to interrupt a pathway critical
to HIV replication (19,20). The goal of this speciﬁc Integrated
Preclinical/Clinical Program (IPCP) is to identify an NK-1R
antagonist that is: (a) active as an anti-HIV agent through
interaction with chemokine/cytokine receptors (Project 1); (b)
speciﬁc for chemokine and G-protein coupled receptors
(Project 2); (c) safe for use in SIV (simian immunodeﬁciency
virus)-infected non-human primates and provides proof of
concept related to antiviral, immunomodulatory, and neuro-
behavioral effects (Project 3); and (d) safe in humans and has
positive immunomodulatory effects (Project 4). All projects
contribute to understanding the basic virologic, molecular and
cellular immunologic mechanisms of Substance P, NK-1R
antagonists, and HIV/SIV infection.
A key element in the IPCP is the integration of modeling
and simulation strategies to support the various projects as
well as inform the administrative core which is ultimately
responsible for project and overall grant decision making (go/
no-go decisions, candidate selection, etc). Speciﬁcally, com-
putational techniques are employed to challenge the “drugg-
ability” of the candidate agents. In silico ADME (absorption,
distribution, metabolism and elimination) techniques are used
as part of the ranking criteria by which we will prioritize the
advancement of selected agents. The approach enables the
calculation of molecular descriptors and prediction of drug-
likeness data using 2D molecular structures, and without the
need for special computational chemistry knowledge. As
pharmacology and biology/mechanism data are generated
for the various agents (Projects 1 and 2), the generalizability
of structure-activity and structure-pharmacokinetic relation-
ships for this compound class will be explored. Figure 3
illustrates the integration of quantitative pharmacology ap-
plication across projects for this IPCP.
The NK1R project is dependent on two primary pro-
gression pathways: 1) examine the extent to which the NK1R
antagonist aprepitant is a suitable agent for antiretroviral
therapy in NeuroAIDS patients based on exposure-response
criteria constructed from its presumed actions, and 2)
examine the correlation between aprepitant preclinical phar-
macology, druggability criteria and PK/PD relationships to
generalize and ultimately rank suitable back-up compounds.
Within the ﬁrst pathway there is a progression of experiments,
predeﬁned criteria for stage advancement and decision trees
that guide the overall progression. These are facilitated by
modeling and simulation exercises permitting scenario testing
for subsequent experiments and testing of assumptions funda-
mental to key decision criteria for the overall program. One of
the essential bridges in this IPCP is the suitability of an SIV
pharmacology/disease model to predict success outcomes in
HIV. In the series of experiments that has ensued, the PK/PD
of aprepitant in SIV-infected animals have been characterized
and used in conjunction with relevant data from chemotherapy-
induced nausea and vomiting patients to build simulation
models that project response in HIV-infected patients. The use
of modeling and simulation to advance compound progression
of antiretroviral agents recently reviewed by Barrett (21)
contains a more thorough description of this case study.
CONCLUSION
It is clear that academic medical centers will be an impor-
tant player in the evolving R&D paradigms which will guide the
discovery of new molecular entities in the years to come.
Translational research is an approach that relies heavily on the
interaction between basic and clinical scientists and the appro-
priate communication of ideas, hypotheses and experimental
designs to evaluate disease therapies. The concept of quantita-
tive pharmacology is, in essence, a communication platform by
which translational research can be discussed and in which
assumptions, models and simulations are integrated into a
decision-making dialogue. It is also clear that the recent efforts
oftheFDAandNIHreﬂecttherecognitionthatthisskillsetisin
short supply and will require dedicated programs to train future
generations of scientists that conduct translational research.
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